AKRO Company Profile and Key Details

Short-term trend indicators are bearishly aligned (SMA20 0.5%, SMA50 3.27%, SMA200 13.46%). The stock’s 14-day RSI is 69.17 (firm momentum), while the ATR of 0.29 points to tighter daily ranges. The stock remains hovering near 52-week lows, trading -6.42% below its high and over 156.09% above its low.

Akero Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $4.52. This means the shares are trading above this model’s fair value.

Akero Therapeutics, Inc. generated EPS of -$3.75 over the past year. Five-year average earnings growth is -5.28%. Wall Street analysts project EPS growth of -8.05% annually over the next five years. The latest quarter delivered EPS of -$0.99. The next quarter is forecast at -$0.94. Next year's EPS is expected at -$29.29. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 10 Buy ratings, 3 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $109.00 to $50.00. The high target offers 99.45% upside. The low target suggests -8.51% downside. The mean target is $72.00. This offers 31.75% upside. Akero Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended November 07, 2025, missed forecasts by 5.32%. The prior quarter beat by -11.34%. Over the last six quarters, Apple has recorded several small beats. These include -10.0% in August 09, 2024.

Akero Therapeutics, Inc. has 82.32 million shares outstanding. The public float is 71.11 million shares, elevated short interest at 5.40% of float. This equals 4.32 million shares. The short ratio is 2.33 days. Institutional investors hold 114.14% of the float. Insiders own 1.46%. Skorpios Trust holds 3.27 million shares, Graham G. Walmsley has 1.20 million shares and Cheng Andrew has 526.11 thousand shares. Over the past six months, insider transactions show net selling. They sold 52.80 thousand shares across 16 transactions.

The stock is currently mid-range between its 52-week high and low $21.34 and $58.40. With a market capitalization of about $4.50 billion, Akero Therapeutics, Inc. is classified as a mid-cap and shows lower-than-market volatility (beta ~-0.40). Key stats such as the average daily volume over the past year has been around 2.56 million shares, trading with heavier-than-usual volume. Headquartered in South San Francisco, CA, Akero Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Andrew Cheng, the company employs approximately 69 people and listed since June 20, 2019. Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health.

Our AI price prediction model suggests that Akero Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 0.95%, with price expected at $55.17 by December 23, 2025, within a range of $54.36 to $56.05 3-Month Outlook: Projected rise of 43.77%, reaching $78.57 by March 09, 2026, with a range of $77.33 to $79.82. 1-Year Outlook: Projected loss of -1.08%, with price at $54.06 by December 09, 2026, within a range of $49.48 to $59.50.

Akero Therapeutics, Inc. (NASDAQ:AKRO) shares are up 96.44% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Akero Therapeutics, Inc. trading at a premium to the broader market with a P/E of -15.73. Analyst sentiment is mixed, with the majority of ratings in Neutral territory and a mean price target of $59.65, suggesting 9.15% upside. Our AI forecast model points to short-term strength (0.95% over two weeks), a medium-term rise (43.77% over three months), and a longer-term loss (-1.08% over one year), with expected trading ranges indicating moderate volatility.

Akero Therapeutics, Inc. trades at a P/E ratio of -15.73, slightly below the S&P 500 average, with a price-to-sales ratio of 1124684.53 and a price-to-book ratio of 4.35 trading at moderately above to book value. The P/FCF stands at -17.75, also below market averages.